Factors to watch on Sept 1

September 1, 2016 5:36 AM

16 0

Novartis is folding activities of its Cell and Gene Therapy unit into other business and research locations, eliminating 120 positions, the Swiss drugmaker said on Wednesday. The move intensifies a corporate makeover begun this year as it focuses on high-growth areas including cancer immunotherapy.

Swiss drug maker Roche Holding said its cancer immunotherapy Tecentriq (atezolizumab) had helped people, diagnosed with a specific type of lung cancer, live significantly longer compared with chemotherapy in a Phase III study.

Also read: Fyffes recommends 751 mln euro takeover by Japan's Sumitomo

Read more

To category page

Loading...